Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI

Kubo, Akinori; Suda, Goki; Kimura, Megumi; Maehara, Osamu; Tokuchi, Yoshimasa; Kitagataya, Takashi; Ohara, Masatsugu; Yamada, Ren; Shigesawa, Taku; Suzuki, Kazuharu; Kawagishi, Naoki; Nakai, Masato; Sho, Takuya; Natsuizaka, Mitsuteru; Morikawa, Kenichi; Ogawa, Koji; Ohnishi, Shunsuke; Sakamoto, Naoya

Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI

Kubo, Akinori; Suda, Goki; Kimura, Megumi et al.

Cancers, 2021, 13(14), 3633

Permalink : https://hdl.handle.net/2115/82549

このアイテムのアクセス数:570件（2026-08-27 11:08 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
https://doi.org/10.3390/cancers13143633			110

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/82549
タイトル	Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI
著者	Kubo, Akinori ; Suda, Goki ; Kimura, Megumi ; Maehara, Osamu ; Tokuchi, Yoshimasa ; Kitagataya, Takashi ; Ohara, Masatsugu ; Yamada, Ren ; Shigesawa, Taku ; Suzuki, Kazuharu ; Kawagishi, Naoki ; Nakai, Masato ; Sho, Takuya ; Natsuizaka, Mitsuteru ; Morikawa, Kenichi ; Ogawa, Koji ; Ohnishi, Shunsuke ; Sakamoto, Naoya
著者名 Kubo, Akinori
e-Rad_Researcher 20447460 著者名 Suda, Goki
著者名 Kimura, Megumi
著者名 Maehara, Osamu
著者名 Tokuchi, Yoshimasa
著者名 Kitagataya, Takashi
著者名 Ohara, Masatsugu
著者名 Yamada, Ren
著者名 Shigesawa, Taku
著者名 Suzuki, Kazuharu
著者名 Kawagishi, Naoki
著者名 Nakai, Masato
著者名 Sho, Takuya
著者名 Natsuizaka, Mitsuteru
著者名 Morikawa, Kenichi
著者名 Ogawa, Koji
著者名 Ohnishi, Shunsuke
e-Rad_Researcher 10334418 著者名 Sakamoto, Naoya
言語	英語
キーワード	CTNNB-1
	HCC with iso-high intensity in the hepatobiliary phase of EOB-MRI
	Lenvatinib
発行日	2021-07
出版者	MDPI
収録物名	Cancers
巻(号)	13(14)
ページ	3633
抄録	In hepatocellular carcinoma (HCC), CTNNB-1 mutations, which cause resistance to immune checkpoint inhibitors, are associated with HCC with iso-high intensity in the hepatobiliary phase of gadoxetic acid-enhanced magnetic resonance imaging (EOB-MRI) in resectable HCC; however, analyses on unresectable HCC are lacking. This study analyzed the prevalence, characteristics, response to lenvatinib, and CTNNB-1 mutation frequency in unresectable HCC with iso-high intensity in the hepatobiliary phase of EOB-MRI. In 52 patients with unresectable HCC treated with lenvatinib, the prevalence of iso-high intensity in the hepatobiliary phase of EOB-MRI was 13%. All patients had multiple HCCs, and 3 patients had multiple HCCs with iso-high intensity in the hepatobiliary phase of EOB-MRI. Lenvatinib response to progression-free survival and overall survival were similar between patients with or without iso-high intensity in the hepatobiliary phase of EOBMRI. Seven patients (three and four patients who had unresectable HCC with or without iso-high intensity in the hepatobiliary phase of EOB-MRI, respectively) underwent genetic analyses. Among these, two (67%, 2/3) who had HCC with iso-high intensity in the hepatobiliary phase of EOB-MRI carried a CTNNB-1 mutation, while all four patients who had HCC without iso-high intensity in the hepatobiliary phase of EOB-MRI did not carry the CTNNB-1 mutation. This study's findings have clinical implications for the detection and treatment of HCC with iso-high intensity in the hepatobiliary phase of EOB-MRI.
資源タイプ	学術雑誌論文
出版タイプ	Version of Record
関連情報 (isIdenticalTo)	出版社版DOI https://doi.org/10.3390/cancers13143633